JNJ-39220675, an aryloxypyridine amide, is a selective histamine H3 receptor antagonist. JNJ-39220675 was under development for the treatment of allergic rhinitis.

Sufotidine is a triazolamine derivative patented by Glaxo Group Ltd. as long-acting histamine H2-blocker useful for the treatment of peptic ulceration and oesophagitis. In phase II clinical treatment with sufotidine decreases median integrated 24-hour intragastric acidity by 95% compared with placebo. Twice daily sufotidine maintained the pH above 3 throughout the 24 h. Unfortunately, no further development report has been published and it seems, that Sufotidine development currently discontinued.

Sucralox is a saccharated aluminum hydroxide patented by Combe, Inc. as antacid agent. Sucralox shows potent antacid properties in vitro and in vivo. Currently Sucralox is used to support gastric and intestinal health in horses.

Sulfaclomide is a sulfonamide derivative structurally similar to p-aminobenzoic acid, patented by VEB Farbenfabrik Wolfen as antibacterial agent useful for the treatment of infectious diseases. Sulfanilamide competes with p-aminobenzoic acid for the bacterial enzyme dihydropteroate synthase, thereby preventing the incorporation of p-aminobenzoic acid into dihydrofolic acid, the immediate precursor of folic acid. This leads to an inhibition of bacterial folic acid synthesis and de novo synthesis of purines and pyrimidines, ultimately resulting in cell growth arrest and cell death.

Pentomone is a nonsteroidal antiandrogen developed by Lilly Company for postmenopausal patients with metastatic breast cancer who have been previously treated with tamoxifen. It is a prostate growth inhibitor.

Cytochalasin B is a cell-permeable alkaloid, isolated from a fungus Helminthosporium dematioideum. Cytochalasin B is an inhibitor of actin polymerization through binding to the fast-growing (barbed) end of F-actin filaments. Cytochalasin is used in studies of actin polymerization, cell division, and cell movement. The compound also inhibits glucose transporters GLUT1,3 and 4 and was investigated in a clinical trial to prevent restenosis after angioplasty surgery.

Draflazine is a member of the lidoflazine. Draflazine is a potent inhibitor of equilibrative nucleoside transporters (ENTs). It is more selective for ENT1 relative to ENT2. Draflazine is cardioprotective due to potentiation of receptor-mediated effects of adenosine in the ischemic myocardium. It has also been tested for enhancing cardiac functionality in isolated hearts during storage or transport for transplant operations. Draflazine exhibits overactive bladder activity. It is not yet approved for clinical use.

Cetocycline (formerly chelocardin or cetotetrine) is tetracycline derivative with potent antibacterial activity against a number of Gram-positive and Gram-negative multi-resistant pathogens. Cetocycline was found to be more active than tetracycline against many clinical isolates of aerobic gram-negative bacilli, but is less active against staphylococci, and has no activity against Pseudomonas. At low concentrations, like classical tetracyclines, chelocardin induces the proteomic signature for peptidyl transferase inhibition demonstrating that protein biosynthesis inhibition is the dominant physiological challenge. At higher concentrations B. subtilis mainly responds to membrane stress indicating that at clinically relevant concentrations the membrane is the main antibiotic target of chelocardin.

Etomoxir is an irreversible inhibitor of carnitine O-palmitoyltransferase (CPT) I. It inhibits fatty acid oxidation and fatty acid and cholesterol synthesis in an enantiomer-selective manner: only the R-enantiomer of etomoxir inhibits fatty acid oxidation, S-enantiomer inhibits fatty acid and cholesterol synthesis but not fatty acid oxidation. Etomoxir was studied for the treatment of congestive heart failure and type II diabetes, however, its development was discontinued.